• Conference
  • Earn CE
  • Free Samples
  • Magazine
  • Subscribe
  • Videos
    • Recent Quotes
    My Watchlist
    Indicators
    Dental Market Index
    Markets
    Stocks
    ETFs
    Tools
    Overview
    News
    Currencies
    International
    Treasuries

    Daiichi Sankyo Ltd (OP: DSKYF )

    35.65 UNCHANGED
    Streaming Delayed Price Updated: 3:27 PM EDT, Jul 11, 2024 Add to My Watchlist
    Quote
    Overview Detailed Quote Charting Historical Prices
    News
    All News News Headlines Press Releases
    Research
    Quarterly Reports Insider Filings Other Filings

    Price and Volume

    Detailed Quote
    Volume 0
    Open 35.65
    Bid (Size) N/A (0)
    Ask (Size) N/A (0)
    Prev. Close 35.65
    Today's Range 35.65 - 35.65
    52wk Range 23.45 - 37.30
    Shares Outstanding N/A
    Dividend Yield N/A
    Chart for (: )
    Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

    Top News

    More News
    FDA Declines To Approve Merck-Daiichi Sankyo Partnered Lung Cancer Drug
    The FDA issued a Complete Response Letter for Daiichi Sankyo and Merck's BLA for patritumab deruxtecan targeting EGFR-mutated NSCLC due to third-party manufacturing facility inspection findings. The... 
    Via Benzinga
    Exposures Product Safety
    5 Biotech Stocks With Key Catalysts This Week: Merck, Intellia, Verona, And More
    Biotech investing is risk-fraught but the returns could be staggering if one chooses to take the educated approach. 
    Via Benzinga

    Performance

    YTD
    +35.45%
    +35.45%
    1 Month
    -2.82%
    -2.82%
    3 Month
    +24.61%
    +24.61%
    6 Month
    +17.97%
    +17.97%
    1 Year
    +29.68%
    +29.68%

    More News

    Read More
    Why Is AstraZeneca Stock Trading Lower On Tuesday?
    Via Benzinga
    Double Good News For AstraZeneca's Breast Cancer Drugs
    Via Benzinga
    AstraZeneca/Daiichi's Flagship Drug Enhertu Secures Accelerated FDA Approval For Pretreated Cancer Patients With Solid Tumor
    Via Benzinga
    Exposures Product Safety
    Daiichi, Zymeworks Terminate Seven Year-Cancer Antibody Pact
    Via Benzinga
    Daiichi Sankyo Seeks Approval In Japan For Its mRNA-Based COVID-19 Vaccine
    Via Benzinga
    What's Going On With Pfizer Stock Today?
    Via Benzinga
    Merck Signs Multi-Billion Deal With Japan's Daiichi Sankyo For Cancer Therapy Drug Development
    Via Benzinga
    Better Than Chemotherapy - AstraZeneca/Daiichi Sankyo Partnered Cancer Drug Meets Primary Goal In Breast Cancer Setting
    Via Benzinga
    AstraZeneca's Reinforces Hold In Lung Cancer Settings: Touts Promising Data From Three Trials
    Via Benzinga
    FDA Greenlights Daiichi Sankyo's Blood Cancer Drug, A Promising Competitor to Novartis' Rydapt
    Via Benzinga
    AstraZeneca Shares Under Pressure On Some Adverse Events In Late-Stage Lung Cancer Drug Trial
    Via Benzinga
    AstraZeneca-Daiichi Sankyo's Flagship Cancer Drug Shows Meaningful, Durable Responses In Other Solid Tumor Setting
    Via Benzinga
    AstraZeneca - Daiichi Sankyo's Enhertu Wins European Approval For Gastric Cancer, CHMP Backs Other Cancer Drugs
    Via Benzinga
    European Medicines Agency's Advisory Committee Backs Approval Of AstraZeneca's Three Cancer Drugs
    Via Benzinga
    With Upcoming Contentious Meeting, This Analyst Cuts Price Target On Spectrum Pharma
    Via Benzinga
    Seagen Suffers Loss In Arbitration Dispute Over ADC Technology
    Via Benzinga
    AstraZeneca-Daiichi's Flagship Breast Cancer Drug Improves Survival In Late-Stage Study
    Via Benzinga
    Daiichi-AstraZeneca's Flagship Cancer Drug Scores FDA Approval For Lung Cancer Harboring HER2 Mutation
    Via Benzinga
    AstraZeneca's Dato-DXd-Based Combo Therapies Show Promising Activity In Lung Cancer Patients
    Via Benzinga
    The Daily Biotech Pulse: FDA Tentatively Approves Avadel's Narcolepsy Drug, European Approval Broadens AstraZeneca's Enhertu in Breast Cancer, Pharma Giants' Earnings
    Via Benzinga
    AstraZeneca's Enhertu Wins European Approval For Pretreated Breast Cancer Setting
    Via Benzinga
    The Daily Biotech Pulse: CHMP Backs AstraZeneca's Breast Cancer Therapies, Ipsen Buys Epizyme, FDA Holds For Nuvation Bio, Astellas Studies
    Via Benzinga
    EMA's Advisory Committee Backs Approval For AstraZeneca's Targeted Breast Cancer Therapies
    Via Benzinga
    Data & News supplied by www.cloudquote.io
    Stock quotes supplied by Barchart
    Quotes delayed at least 20 minutes.
    By accessing this page, you agree to the following
    Privacy Policy and Terms and Conditions.